Autoinjectors Market Size & Share 2026-2035

Autoinjectors Market Size

The global autoinjectors market was estimated at USD 115 billion in 2025. The market is expected to grow from USD 127.9 billion in 2026 to USD 430.8 billion in 2035, at a CAGR of 14.4% during the forecast period, according to the latest report published by Global Market Insights Inc. The market is driven by numerous factors, such as growing demand for targeted therapies, and availability of generic autoinjectors globally, among other factors.

Autoinjectors are drug delivery devices that inject a pre-set dose of drug into the body automatically, usually by way of a needle. They are used to administer drugs for self-injection most frequently for diseases such as allergies, diabetes, rheumatoid arthritis, and other long-term diseases. Autoinjectors are simple to use, typically with a spring mechanism for the administration of the drug with the minimum effort, making them particularly well suited for those patients who require multiple injections.

Rising patient preference towards self-administration of medication is expected to fuel the industry's growth. AbbVie, Eli Lilly, Novartis, Johnson & Johnson, and Sanofi are among the leading players operating in the market. These companies primarily focus on product innovation, capacity expansion, and research and development to enhance accessibility and support the growing demand for autoinjector-based drug delivery systems.

The market has increased from USD 85.9 billion in 2022 and reached USD 103.9 billion in 2024, with a historic growth rate of 10%. The increasing incidence of diabetes is a major driver for the growth of the market, as a growing patient population requires effective and convenient drug delivery solutions. According to the International Diabetes Federation (IDF), approximately 589 million adults (aged 20–79 years) were living with diabetes globally in 2024, and this number is projected to rise to 853 million by 2050. This sharp increase is driving demand for user-friendly, self-administered drug delivery systems such as autoinjectors, particularly for insulin and GLP‑1 therapies. As patients seek more convenient and reliable ways to manage chronic conditions at home, autoinjectors are becoming essential tools for improving treatment adherence and overall disease management.

Additionally, the rising incidence of severe allergic reactions (anaphylaxis) is further contributing to the demand for autoinjectors, particularly epinephrine delivery devices. The need for rapid, emergency treatment of anaphylaxis has led to widespread adoption of portable autoinjectors that enable immediate self-administration in critical situations. Together, the rising burden of diabetes and anaphylaxis is significantly expanding the application scope of autoinjectors, thereby driving sustained growth in the global market.

The availability of generic autoinjectors globally is playing a key role in expanding market access and driving adoption by reducing treatment costs and improving affordability. Generic alternatives, particularly in the anaphylaxis segment, are enabling broader patient access to life-saving therapies. For instance, the Teva Epinephrine Auto‑Injector, a generic alternative to EpiPen, has significantly improved the affordability and availability of emergency allergy treatment. The presence of such cost-effective options is encouraging greater adoption across both developed and emerging markets, while also increasing competition among manufacturers. As more generic and biosimilar autoinjectors enter the market, they are expected to enhance accessibility, support wider patient reach, and contribute to sustained growth in the global market.

Autoinjectors Market Trends

The advancements in autoinjector technologies play a critical role in driving market growth by enhancing ease of use, improving patient safety, and enabling precise drug delivery for complex therapies.

• Continuous innovations in device design and functionality are making autoinjectors more user-friendly, reliable, and suitable for a wide range of therapeutic applications.
• Advanced autoinjectors are increasingly being developed with features such as ergonomic designs, hidden needles, automated needle insertion, and controlled drug delivery mechanisms, which reduce pain and anxiety associated with injections. In addition, the integration of smart technologies such as Bluetooth connectivity, dose tracking, and reminder systems enables better treatment adherence and real-time monitoring. These developments are particularly beneficial for patients managing chronic conditions, as they simplify the injection process and improve overall user experience.
• These technological advancements significantly improve patient compliance and reduce the risk of dosing errors, which is critical for therapies requiring strict dosing accuracy such as biologics and GLP‑1 drugs.
• For instance, BD’s Intevia autoinjector system offers prefilled, ready-to-use functionality with automated injection control and improved safety features. Additionally, SHL Medical’s Molly autoinjector platform provides scalable, customizable solutions for high-volume biologic delivery, supporting both usability and manufacturing efficiency.
• Collectively, these technological innovations highlight a strong industry focus on patient-centric design, digital integration, and precision drug delivery, thereby reinforcing advancements in autoinjector technologies as a key factor supporting the sustained growth of the global autoinjector market.

Autoinjectors Market Analysis

Based on type, the autoinjectors market is segmented into disposable and reusable. The disposable segment accounted for a dominant market share of 66.5% in 2025, driven by its convenience, ease of use, and reduced risk of cross-contamination. The segment is expected to reach USD 280.9 billion by 2035, growing at a CAGR of 14.2% during the forecast period.

• The disposable segment represented the dominating type category in the autoinjector market, driven by its widespread adoption, ease of use, and high safety profile across multiple therapeutic applications. Disposable autoinjectors are prefilled and designed for single use, eliminating the need for cartridge replacement and reducing the risk of contamination and dosing errors.
• These devices are extensively used for chronic conditions such as diabetes, autoimmune disorders, and anaphylaxis, where consistent and accurate drug delivery is critical. Their ready-to-use design and minimal handling requirements make them highly suitable for home-care settings, thereby reinforcing their dominant position in the market.
• Technological advancements in disposable autoinjectors are further enhancing their performance and adoption, particularly through the integration of patient-friendly features and improved safety mechanisms. Modern devices include hidden needles, automated injection systems, dose completion indicators, and ergonomic designs that reduce patient anxiety and improve adherence to therapy. These innovations are improving patient experience, ensuring reliable drug administration, and increasing the utility of disposable autoinjectors across healthcare settings.
• The reusable segment is projected to expand at a 14.9% CAGR to reach USD 150 billion by 2035. The reusable segment is expected to witness steady growth, supported by its cost-effectiveness and sustainability advantages. Reusable autoinjectors utilize replaceable cartridges, allowing multiple uses with a single device, which reduces long-term costs and environmental impact.
• These devices are particularly preferred in regions and patient groups where cost sensitivity and long-term therapy management are key considerations. As healthcare systems increasingly emphasize cost efficiency and sustainability, reusable autoinjectors are expected to gain traction, complementing the overall growth of the autoinjector market.

Based on the route of administration, the autoinjectors market is segmented into subcutaneous and intramuscular. The subcutaneous segment is projected to expand at a 14.6% CAGR to reach USD 401.9 billion by 2035.

• The subcutaneous segment represented the dominating route of administration in the autoinjector market, driven by the widespread use of biologics and chronic disease therapies that require slow and controlled drug absorption.
• Subcutaneous delivery is preferred for drugs such as insulin, GLP‑1 receptor agonists, and monoclonal antibodies, as it allows for self-administration, reduced pain, and improved patient comfort compared to other injection routes. Additionally, this route supports long-term therapy management in home-care settings, making it highly suitable for conditions such as diabetes, autoimmune diseases, and obesity. The growing pipeline of biologics and targeted therapies, most of which are formulated for subcutaneous delivery, continues to reinforce the dominance of this segment.
• The intramuscular segment is projected to expand at 12.7% CAGR to reach USD 28.9 billion by 2035. The intramuscular segment is expected to witness steady growth, supported by its rapid drug absorption and suitability for emergency and high-potency therapies. Intramuscular autoinjectors are commonly used in acute care scenarios, such as anaphylaxis (e.g., epinephrine autoinjectors) and emergency treatments where fast systemic circulation is critical. This route is also gaining attention in applications such as vaccine delivery and certain biologics requiring quicker onset of action. Increasing awareness of emergency preparedness, along with the need for reliable and fast-acting drug delivery systems, is driving the adoption of intramuscular autoinjectors, particularly in institutional and emergency care settings.

Based on therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, and other therapies. The diabetes segment is anticipated to obtain the highest CAGR growth of 15.1% during the forecast period.

• The increasing number of cases of diabetes worldwide, mainly type 1 and type 2 diabetes, is fueling the growth for insulin and other injectable products. Since diabetes is a long-term disease that must be medicated continuously, the usage of autoinjectors proves to be an easier and less painful way of injecting insulin, thus boosting growth in this segment.
• Additionally, ongoing development in insulin delivery devices, like prefilled pens and intelligent autoinjectors, is facilitating better management of diabetes by patients. These devices have more accurate dosing, improved tracking capabilities, and easier usability, making them more popular with patients, hence driving the segment's growth at a faster pace.
• For instance, NovoPen Echo Plus, a smart insulin pen offered by Novo Nordisk, records dosing information and integrates with digital platforms for better diabetes management. Similarly, Eli Lilly and Company also provides their own Tempo Pen + Tempo Smart Button, which is a pen integrated with a Bluetooth-enabled tempo smart button that can be affixed to the pen, and it relays dose information to the mobile application.
• The rheumatoid arthritis segment is projected to expand at a 14.8% CAGR to reach USD 113.1 billion by 2035. The rheumatoid arthritis segment represents a major therapeutic application in the autoinjector market, driven by the high prevalence of autoimmune disorders and the widespread use of biologic therapies requiring long-term administration. Patients with rheumatoid arthritis often need frequent and consistent dosing of monoclonal antibodies and biologics, making autoinjectors a preferred delivery method due to their ease of use and reduced manual effort. Additionally, the need to improve patient adherence and reduce hospital dependency is encouraging the adoption of self-injection devices. The availability of biosimilars in autoinjector formats is further supporting growth by improving affordability and access.
• The multiple sclerosis segment is projected to expand at a 13.7% CAGR to reach USD 55.6 billion by 2035. The multiple sclerosis segment is experiencing steady growth, supported by the increasing use of disease-modifying therapies that require precise and regular administration. Autoinjectors are particularly beneficial for multiple sclerosis patients as they simplify the injection process, reduce injection-site discomfort, and enable better compliance with long-term treatment regimens.
• The anaphylaxis segment is projected to expand at a 13.4% CAGR to reach USD 24.2 billion by 2035. The anaphylaxis segment is witnessing significant demand, driven by the critical need for rapid and emergency drug delivery solutions. Autoinjectors, particularly epinephrine devices, are widely used for the immediate treatment of severe allergic reactions, where timely administration is life-saving. Increasing prevalence of food allergies, environmental triggers, and heightened awareness about emergency preparedness are key factors supporting growth.

Based on end use, the autoinjectors market is segmented into hospital and clinics, homecare settings, and other end users. The homecare settings segment dominated the market with a share of 64.2% in 2025.

• The homecare settings segment dominated the market, supported by the strong shift toward self-administration and patient-centric care models. Patients increasingly prefer home-based treatment due to convenience, reduced healthcare costs, and the ability to manage chronic diseases independently.
• Autoinjectors enable safe and accurate drug delivery without requiring medical assistance, making them highly suitable for long-term therapies such as diabetes, rheumatoid arthritis, and biologics. The growing adoption of telemedicine and remote monitoring solutions is further supporting this trend, allowing healthcare providers to supervise patients virtually while maintaining treatment adherence, reinforcing the dominance of this segment.
• The hospital and clinics segment is projected to expand at a 14.2% CAGR to reach USD 122.6 billion by 2035. The hospitals and clinics segment represents a significant end-user category in the autoinjector market, driven by the need for supervised administration, initial diagnosis, and patient training. Healthcare professionals in these settings are responsible for initiating therapy, ensuring correct injection techniques, and managing complex cases requiring close monitoring.
• Additionally, hospitals play a crucial role in supporting safe and effective use of autoinjectors through patient education and integration with advanced healthcare systems. With the increasing adoption of telemedicine and remote monitoring, hospitals are extending their role beyond in-facility care by enabling patients to self-administer injections at home under virtual supervision. This approach ensures treatment adherence while maintaining a secondary layer of clinical oversight. As a result, hospitals continue to remain a foundational part of the autoinjector ecosystem, bridging in-clinic care with home-based treatment and supporting overall market growth.
• The other end users segment is projected to expand at a 12.9% CAGR to reach USD 24.8 billion by 2035. The other end users segment, which includes emergency services, workplaces, schools, and military settings, is witnessing steady growth due to the rising need for immediate drug administration in non-clinical environments. Autoinjectors are increasingly used in these settings for emergency situations such as anaphylaxis, where rapid response is critical.

 North America Autoinjectors Market

The North America market accounted for a majority share of 46.9% in 2025 and is anticipated to show notable growth over the forecast period.

• The U.S. market was valued at USD 27 billion and USD 29.6 billion in 2022 and 2023, respectively. The market size reached USD 49.2 billion in 2025, growing from USD 32.7 billion in 2024, and is anticipated to grow at a CAGR of 14.5% from 2026 to 2035.
• The North America autoinjector market is experiencing strong growth, driven by the rising prevalence of chronic diseases such as diabetes and arthritis, which are significantly expanding the patient population requiring frequent injectable therapies.
• For instance, according to the Centers for Disease Control and Prevention (CDC), approximately 38.4 million people of all ages in the U.S. were living with diabetes in 2021, with about 78.8% of adults reporting access to a regular source of diabetes care, including healthcare professionals. This reflects a highly engaged patient population requiring continuous treatment. Furthermore, around 53 million U.S. adults were living with arthritis in 2024, a number expected to increase with aging. These conditions often require long-term biologic or insulin-based treatments, thereby driving demand for convenient, self-administered drug delivery solutions such as autoinjectors across the region.
• In addition, technological advancements in autoinjector devices are further accelerating market growth by improving usability, safety, and treatment adherence. Modern autoinjectors are being designed with ergonomic features, hidden needles, automated injection systems, and feedback mechanisms to simplify drug administration for patients.
• The integration of smart technologies such as connectivity and dose tracking is enhancing patient monitoring and compliance. These innovations are making autoinjectors more accessible and user-friendly, supporting their widespread adoption and reinforcing the growth of the autoinjector market in North America.

Europe Autoinjectors Market

Europe accounted for a significant share of the global market and was valued at USD 23.8 billion in 2025.

• The Europe autoinjector market is experiencing steady growth, driven by the increasing demand for targeted therapies across the region. The shift toward precision medicine, particularly in the treatment of autoimmune diseases, oncology, and metabolic disorders, is driving the adoption of biologic drugs that require precise and controlled delivery mechanisms.
• Autoinjectors are becoming a preferred mode of administration for these therapies due to their ability to ensure accurate dosing, improve patient convenience, and support long-term treatment adherence. As targeted therapies continue to expand across therapeutic areas, the demand for advanced drug-delivery devices such as autoinjectors is expected to increase significantly.
• Additionally, the rising incidence of diabetes and anaphylaxis is further contributing to market growth by expanding the need for self-administered injectable treatments. According to the World Health Organization (WHO), an estimated 74 million adults and around 300,000 children and adolescents are living with diabetes in the WHO European Region in 2024, highlighting the growing disease burden. This increasing prevalence is driving demand for insulin and GLP‑1 therapies delivered via autoinjectors. At the same time, the need for rapid-response treatments for severe allergic reactions is supporting the adoption of epinephrine autoinjectors across the region. These factors collectively strengthen the role of autoinjectors in chronic and emergency care, thereby supporting the sustained growth of the Europe autoinjector market.

Asia Pacific Autoinjectors Market

The Asia Pacific market accounted for a substantial share of the market and was valued at USD 17 billion in 2025.

• The Asia Pacific autoinjector market is witnessing significant growth, driven by rapid demographic shifts and the accelerating aging population across the region. According to UNFPA, the number of older individuals in Asia and the Pacific is increasing at an unprecedented rate, with projections indicating that one in four people in the region will be over 60 years of age by 2050, and the elderly population is expected to triple to nearly 1.3 billion between 2010 and 2050. This large and expanding elderly population is more susceptible to chronic conditions requiring long-term injectable therapies, thereby increasing the need for easy-to-use and reliable drug delivery solutions such as autoinjectors.
• In addition, the evolving healthcare landscape and increasing demand for home-based care are further supporting market expansion in Asia Pacific. As elderly patients often face challenges with frequent hospital visits and manual injections, the demand for self-administration devices that offer convenience, safety, and ease of use is rising.
• Autoinjectors, with their user-friendly design and ability to ensure accurate dosing, are becoming increasingly preferred for managing age-related conditions such as diabetes, autoimmune diseases, and cardiovascular disorders. This convergence of demographic trends and shifting healthcare delivery models is expected to drive sustained adoption of autoinjectors across the region.

Latin America Autoinjectors Market

The Latin America market is anticipated to exhibit remarkable growth during the analysis period.

• The Latin America market is witnessing steady growth, supported by the increasing availability of generic autoinjectors, which is improving affordability and expanding patient access across the region. The introduction of cost-effective alternatives such as generic epinephrine autoinjectors is reducing treatment costs and enabling broader adoption, particularly in price-sensitive healthcare systems. This growing availability is encouraging healthcare providers and patients to shift toward autoinjector-based therapies, thereby increasing penetration in both urban and semi-urban areas.
• Additionally, the rising patient preference for self-administration of medication is further driving market expansion across Latin America. Patients are increasingly opting for convenient and user-friendly drug delivery solutions that allow them to manage chronic conditions such as diabetes, autoimmune disorders, and allergies at home. Autoinjectors, with their ease of use and ability to ensure accurate dosing, are gaining popularity as they reduce the need for frequent clinical visits. This shift toward home-based care and patient-centric treatment approaches is significantly contributing to the sustained growth of the autoinjector market in the region.

Middle East and Africa Autoinjectors Market

The Middle East and Africa market is expected to experience substantial growth over the analysis timeframe.

• The Middle East and Africa (MEA) autoinjector market is gaining momentum, driven by the rising need for emergency care solutions, particularly for severe allergic reactions and anaphylaxis. Increasing awareness about life‑threatening allergies, along with the growing prevalence of food and environmental triggers, is supporting the adoption of epinephrine autoinjectors across schools, households, and healthcare facilities. Governments and healthcare providers are focusing on improving the availability of emergency treatment options, which is creating demand for portable and easy‑to‑use autoinjector devices.
• In addition, the region is benefiting from the gradual entry of cost‑effective and generic autoinjector products, which is improving affordability and accessibility in price-sensitive markets. The introduction of lower-cost alternatives to branded devices is enabling broader patient access, particularly in emerging African and Middle Eastern economies. Combined with increasing partnerships between global manufacturers and regional distributors, this is helping expand market reach and supporting the adoption of autoinjectors for both chronic and emergency therapeutic applications across MEA.

Autoinjectors Market Share

• The autoinjectors industry is highly dynamic, with key players such as AbbVie, Eli Lilly, Novartis, Johnson & Johnson, and Sanofi, which collectively account for about 68% share of the global market.

• Leading players in the autoinjector market are actively expanding their geographic presence and strengthening supply chain capabilities to meet the rapidly growing demand for self-administered drug delivery solutions. Strategic collaborations between pharmaceutical companies and device manufacturers, along with investments in large-scale manufacturing facilities, are enabling faster commercialization and improved accessibility of autoinjector-based therapies across both developed and emerging markets.
• For instance, companies such as AbbVie, Eli Lilly, Novartis, Johnson & Johnson, and Sanofi are increasingly focusing on integrating drug-device combinations, particularly for biologics and chronic disease therapies. These players are investing in expanding production capacity, enhancing delivery device design, and partnering with contract manufacturers to ensure consistent supply. Such initiatives are aimed at addressing rising demand for therapies such as GLP‑1 drugs, autoimmune treatments, and injectable biologics, thereby strengthening market positioning and operational efficiency.
• Collectively, these strategic efforts by leading pharmaceutical players are shaping the competitive landscape, accelerating adoption of autoinjector technologies, and supporting the long-term growth of the global autoinjector market.

Autoinjectors Market Companies

A few of the prominent players operating in the autoinjectors industry include:

• AbbVie
• Amgen
• Antares Pharma
• Becton, Dickinson and Company
• Eli Lilly and Company
• Gerresheimer
• GlaxoSmithKline
• Halozyme
• Johnson & Johnson
• Mylan
• Novo Nordisk
• Owen Mumford
• SHL Medical
• Teva Pharmaceuticals
• West Pharmaceutical Services
• Ypsomed       

• Amgen

Amgen stands well-positioned in the market for autoinjectors with its portfolio of patient-centric, biosimilar, and biologic medicines being delivered via one-touch, easy-to-use SureClick autoinjector systems meant for home use. With its integration of highly advanced delivery technologies with therapies used to treat long-term conditions like rheumatoid arthritis and osteoporosis, Amgen is well-positioned in effective solutions for drug delivery.

• Eli Lilly and Company

Eli Lilly is a leading company in the autoinjector market with its range of diabetes and autoimmune therapy products such as Emgality and Trulicity pens. The patient-developed injectors are easy to administer. The union of clinical performance and easy-to-use administration has turned Eli Lilly's autoinjectors into a doctor- and patient-preferred product.

Autoinjectors Industry News:

• In October 2024, BD, a leading global medical technology company, announced a strategic collaboration with Ypsomed, a leading developer of injection systems, to advance self-injection solutions for high-viscosity biologic drugs. This strategic partnership enabled BD to strengthen its capabilities in delivering advanced self-injection solutions, expand its product portfolio for biologic drug delivery, and enhance its competitiveness in the growing autoinjectors market.
• In November 2024, Amneal Pharmaceuticals announced the resubmission to the U.S. Food and Drug Administration (FDA) of its new drug application (NDA) for dihydroergotamine (DHE) prefilled syringe autoinjector. The FDA previously issued a complete response letter due to facility inspection issues, prompting Amneal to transfer production in-house.
• In May 2023, Coherus BioSciences announced the U.S. launch of the UDENYCA Autoinjector. This product is a single-dose, prefilled autoinjector for pegfilgrastim (pegfilgrastim-cbqv) that can be administered in both in-office and at-home settings. The UDENYCA Autoinjector is designed to offer patients greater choice, independence, and flexibility in their treatment following chemotherapy.
• In October 2022, Ypsomed announced the launch of YpsoMate 5.5 autoinjector, which is compatible with liquid medications ranging from 1.5 to 5.5 ml. The YpsoMate 5.5 is the last addition to the ever growing YsoMate family of devices and is built on the well-known technology of YpsoMate 2.25 Pro.

The global autoinjectors market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Type 

• Disposable
• Reusable

Market, By Route of Administration

• Subcutaneous
• Intramuscular

Market, By Therapy

• Rheumatoid arthritis
• Multiple sclerosis
• Anaphylaxis
• Diabetes
• Other therapies

Market, By End Use

• Hospital and clinics
• Homecare settings
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE